Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Possibly Marketed Outside US

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Acetylcholinesterase

3

P2X purinoceptor 3

3

Sodium channel protein type V alpha subunit

3

sodium channel activity

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Arrhythmia

3

Atrial fibrillation and flutter

3

Pain

3

Postoperative pain

3

Pre-excitation syndromes

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Palliative

3

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Rosendahl, H.V.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

FDA UNII

3

PUBCHEM

3

EPA CompTox

2

EVMPD

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

LAPPACONITINE HYDROBROMIDE

HTD60494V5

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Acetylcholinesterase

P2X purinoceptor 3

Sodium channel protein type V alpha subunit

sodium channel activity

Sodium channel protein type V alpha subunit

Conditions:

Supraventricular tachycardia

Pre-excitation syndromes

Postoperative pain

Premature depolarization, unspecified

Atrial fibrillation and flutter

Ventricular tachycardia

Lappaconitine is an alkaloid isolated from the root of Aconltitum sinomantanum Nakai. It has a strong analgesic activity that does not involve the opioid receptor. It was shown to have class-I antiarrhythmic action and irreversibly blocks cloned huma...

n heart (hH1) channels by binding to the site 2 receptor.

LAPPACONITINE

Y4M5974F7Z

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Acetylcholinesterase

P2X purinoceptor 3

Sodium channel protein type V alpha subunit

sodium channel activity

Sodium channel protein type V alpha subunit

Conditions:

Supraventricular tachycardia

Pre-excitation syndromes

Postoperative pain

Premature depolarization, unspecified

Atrial fibrillation and flutter

Ventricular tachycardia

Lappaconitine is an alkaloid isolated from the root of Aconltitum sinomantanum Nakai. It has a strong analgesic activity that does not involve the opioid receptor. It was shown to have class-I antiarrhythmic action and irreversibly blocks cloned huma...

n heart (hH1) channels by binding to the site 2 receptor.

LAPPACONITINE HYDROCHLORIDE

3W1334H51X

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Acetylcholinesterase

P2X purinoceptor 3

Sodium channel protein type V alpha subunit

sodium channel activity

Sodium channel protein type V alpha subunit

Conditions:

Supraventricular tachycardia

Pre-excitation syndromes

Postoperative pain

Premature depolarization, unspecified

Atrial fibrillation and flutter

Ventricular tachycardia

Lappaconitine is an alkaloid isolated from the root of Aconltitum sinomantanum Nakai. It has a strong analgesic activity that does not involve the opioid receptor. It was shown to have class-I antiarrhythmic action and irreversibly blocks cloned huma...

n heart (hH1) channels by binding to the site 2 receptor.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1